Lory Santarelli

Prof. Lory Santarelli

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2017 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
Marco TomasettiMarco Tomasetti
Marco Tomasetti
Wan LeeWan Lee
Wan Lee
LSLory Santarelli
Lory Santarelli
JNJiri Neuzil
Jiri Neuzil
Malignant progression is greatly affected by dynamic cross-talk between stromal and cancer cells. Exosomes are secreted nanovesicles that have key roles in cell–cell communication by transferring nucleic acids and proteins to target cells and tissues. Recently, MicroRNAs (miRs) and their delivery in exosomes have been implicated in physiological and pathological processes. Tumor-delivered miRs, interacting with stromal cells in the tumor microenvironment, modulate tumor progression, angiogenesis, metastasis and immune escape. Altered cell metabolism is one of the hallmarks of cancer. A number of different types of tumor rely on mitochondrial metabolism by triggering adaptive mechanisms to optimize their oxidative phosphorylation in relation to their substrate supply and energy demands. Exogenous exosomes can induce metabolic reprogramming by restoring the respiration of cancer cells and supress tumor growth. The exosomal miRs involved in the modulation of cancer metabolism may be potentially utilized for better diagnostics and therapy.

10 October 2009 in Biogerontology
Verified
Journal Article
Closed access
PDF file
Marco MalavoltaMarco Malavolta
Marco Malavolta
RGRobertina Giacconi
Robertina Giacconi
FPFrancesco Piacenza
Francesco Piacenza
LSLory Santarelli
Lory Santarelli
CCCatia Cipriano
Catia Cipriano
EMEugenio Mocchegiani
Eugenio Mocchegiani

10 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FGFranco Grimolizzi
Franco Grimolizzi
FMFederica Monaco
Federica Monaco
FLFrancesca Leoni
Francesca Leoni
Massimo BracciMassimo Bracci
Massimo Bracci
SSSara Staffolani
Sara Staffolani
LSLory Santarelli
Lory Santarelli
Lung cancer is one of the leading causes of cancer-related deaths. It is diagnosed mostly at the locally advanced or metastatic stage. Recently, micro RNAs (miRs) and their distribution in circulation have been implicated in physiological and pathological processes. In this study, miR-126 was evaluated in serum, exosome and exosome-free serum fractions in non-small cell lung cancer (NSCLC) patients at early and advanced stages, and compared with healthy controls. Down-regulation of miR-126 was found in serum of advanced stage NSCLC patients. In healthy controls, circulating miR-126 was equally distributed between exosomes and exosome-free serum fractions. Conversely, in both early and advanced stage NSCLC patients, miR-126 was mainly present in exosomes. Different fractions of miR-126 in circulation may reflect different conditions during tumour formation. Incubation of exosomes from early and advanced NSCLC patients induced blood vessel formation and malignant transformation in human bronchial epithelial cells. On the other hand, exosome-enriched miR-126 from normal endothelial cells inhibited cell growth and induces loss of malignancy of NSCLC cells. These findings suggest a role of exo-miRs in the modulation of the NSCLC microenvironmental niche. Exosome-delivered miRs thus hold a substantial promise as a diagnostics biomarker as well as a personalized therapeutic modality.

1 September 1995 in International Journal of Immunopharmacology
Verified
Journal Article
Closed access
EMEugenio Mocchegiani
Eugenio Mocchegiani
LSLory Santarelli
Lory Santarelli
MMMario Muzzioli
Mario Muzzioli
NFNicola Fabris
Nicola Fabris

1 May 2012 in Clinical Biochemistry
Verified
Journal Article
Closed access
Marco TomasettiMarco Tomasetti
Marco Tomasetti
SSSara Staffolani
Sara Staffolani
LNLinda Nocchi
Linda Nocchi
JNJiri Neuzil
Jiri Neuzil
ESElisabetta Strafella
Elisabetta Strafella
LSLory Santarelli
Lory Santarelli

1 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LSLory Santarelli
Lory Santarelli
ESElisabetta Strafella
Elisabetta Strafella
SSSara Staffolani
Sara Staffolani
MAMonica Amati
Monica Amati
MEMonica Emanuelli
Monica Emanuelli
Marco TomasettiMarco Tomasetti
Marco Tomasetti
Improved detection methods for diagnosis of malignant pleural mesothelioma (MPM) are essential for early and reliable detection as well as treatment. Since recent data point to abnormal levels of microRNAs (miRNAs) in tumors, we hypothesized that a profile of deregulated miRNAs may be a marker of MPM and that the levels of specific miRNAs may be used for monitoring its progress. miRNAs isolated from fresh-frozen biopsies of MPM patients were tested for the expression of 88 types of miRNA involved in cancerogenesis. Most of the tested miRNAs were downregulated in the malignant tissues compared with the normal tissues. Of eight significantly downregulated, three miRNAs were assayed in cancerous tissue and adjacent non-cancerous tissue sample pairs collected from 27 formalin-fixed, paraffin-embedded MPM tissues by quantitative RT-PCR. Among the miRNAs tested, only miR-126 significantly remained downregulated in the malignant tissues. Furthermore, the performance of the selected miR-126 as biomarker was evaluated in serum samples of asbestos-exposed subjects and MPM patients and compared with controls. MiR-126 was not affected by asbestos exposure, whereas it was found strongly associated with VEGF serum levels. Levels of miR-126 in serum, and its levels in patients' serum in association with a specific marker of MPM, SMRPs, correlate with subjects at high risk to develop MPM. We propose miR-126, in association with SMRPs, as a marker for early detection of MPM. The identification of tumor biomarkers used alone or, in particular, in combination could greatly facilitate the surveillance procedure for cohorts of subjects exposed to asbestos.